<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by...
Ausführliche Beschreibung
Autor*in: |
Ettore Capoluongo [verfasserIn] Nicla La Verde [verfasserIn] Massimo Barberis [verfasserIn] Maria Angela Bella [verfasserIn] Fiamma Buttitta [verfasserIn] Paola Carrera [verfasserIn] Nicoletta Colombo [verfasserIn] Laura Cortesi [verfasserIn] Maurizio Genuardi [verfasserIn] Massimo Gion [verfasserIn] Valentina Guarneri [verfasserIn] Domenica Lorusso [verfasserIn] Antonio Marchetti [verfasserIn] Paolo Marchetti [verfasserIn] Nicola Normanno [verfasserIn] Barbara Pasini [verfasserIn] Matilde Pensabene [verfasserIn] Sandro Pignata [verfasserIn] Paolo Radice [verfasserIn] Enrico Ricevuto [verfasserIn] Anna Sapino [verfasserIn] Pierosandro Tagliaferri [verfasserIn] Pierfrancesco Tassone [verfasserIn] Chiara Trevisiol [verfasserIn] Mauro Truini [verfasserIn] Liliana Varesco [verfasserIn] Antonio Russo [verfasserIn] Stefania Gori [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Diagnostics - MDPI AG, 2012, 9(2019), 4, p 146 |
---|---|
Übergeordnetes Werk: |
volume:9 ; year:2019 ; number:4, p 146 |
Links: |
---|
DOI / URN: |
10.3390/diagnostics9040146 |
---|
Katalog-ID: |
DOAJ086653156 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ086653156 | ||
003 | DE-627 | ||
005 | 20230311052523.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230311s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/diagnostics9040146 |2 doi | |
035 | |a (DE-627)DOAJ086653156 | ||
035 | |a (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Ettore Capoluongo |e verfasserin |4 aut | |
245 | 1 | 0 | |a <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. | ||
650 | 4 | |a ngs | |
650 | 4 | |a <i<brca1/2</i< assays | |
650 | 4 | |a somatic brca | |
650 | 4 | |a parp-1i | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Nicla La Verde |e verfasserin |4 aut | |
700 | 0 | |a Massimo Barberis |e verfasserin |4 aut | |
700 | 0 | |a Maria Angela Bella |e verfasserin |4 aut | |
700 | 0 | |a Fiamma Buttitta |e verfasserin |4 aut | |
700 | 0 | |a Paola Carrera |e verfasserin |4 aut | |
700 | 0 | |a Nicoletta Colombo |e verfasserin |4 aut | |
700 | 0 | |a Laura Cortesi |e verfasserin |4 aut | |
700 | 0 | |a Maurizio Genuardi |e verfasserin |4 aut | |
700 | 0 | |a Massimo Gion |e verfasserin |4 aut | |
700 | 0 | |a Valentina Guarneri |e verfasserin |4 aut | |
700 | 0 | |a Domenica Lorusso |e verfasserin |4 aut | |
700 | 0 | |a Antonio Marchetti |e verfasserin |4 aut | |
700 | 0 | |a Paolo Marchetti |e verfasserin |4 aut | |
700 | 0 | |a Nicola Normanno |e verfasserin |4 aut | |
700 | 0 | |a Barbara Pasini |e verfasserin |4 aut | |
700 | 0 | |a Matilde Pensabene |e verfasserin |4 aut | |
700 | 0 | |a Sandro Pignata |e verfasserin |4 aut | |
700 | 0 | |a Paolo Radice |e verfasserin |4 aut | |
700 | 0 | |a Enrico Ricevuto |e verfasserin |4 aut | |
700 | 0 | |a Anna Sapino |e verfasserin |4 aut | |
700 | 0 | |a Pierosandro Tagliaferri |e verfasserin |4 aut | |
700 | 0 | |a Pierfrancesco Tassone |e verfasserin |4 aut | |
700 | 0 | |a Chiara Trevisiol |e verfasserin |4 aut | |
700 | 0 | |a Mauro Truini |e verfasserin |4 aut | |
700 | 0 | |a Liliana Varesco |e verfasserin |4 aut | |
700 | 0 | |a Antonio Russo |e verfasserin |4 aut | |
700 | 0 | |a Stefania Gori |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Diagnostics |d MDPI AG, 2012 |g 9(2019), 4, p 146 |w (DE-627)718627814 |w (DE-600)2662336-5 |x 20754418 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2019 |g number:4, p 146 |
856 | 4 | 0 | |u https://doi.org/10.3390/diagnostics9040146 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/602ff62a14b84094a5b190129f3575ac |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2075-4418/9/4/146 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2075-4418 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 9 |j 2019 |e 4, p 146 |
author_variant |
e c ec n l v nlv m b mb m a b mab f b fb p c pc n c nc l c lc m g mg m g mg v g vg d l dl a m am p m pm n n nn b p bp m p mp s p sp p r pr e r er a s as p t pt p t pt c t ct m t mt l v lv a r ar s g sg |
---|---|
matchkey_str |
article:20754418:2019----::bc1ioeuaasyooainacrainssretruhtladprmnsfnooynmlcl |
hierarchy_sort_str |
2019 |
callnumber-subject-code |
R |
publishDate |
2019 |
allfields |
10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146 |
spelling |
10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146 |
allfields_unstemmed |
10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146 |
allfieldsGer |
10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146 |
allfieldsSound |
10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146 |
language |
English |
source |
In Diagnostics 9(2019), 4, p 146 volume:9 year:2019 number:4, p 146 |
sourceStr |
In Diagnostics 9(2019), 4, p 146 volume:9 year:2019 number:4, p 146 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) |
isfreeaccess_bool |
true |
container_title |
Diagnostics |
authorswithroles_txt_mv |
Ettore Capoluongo @@aut@@ Nicla La Verde @@aut@@ Massimo Barberis @@aut@@ Maria Angela Bella @@aut@@ Fiamma Buttitta @@aut@@ Paola Carrera @@aut@@ Nicoletta Colombo @@aut@@ Laura Cortesi @@aut@@ Maurizio Genuardi @@aut@@ Massimo Gion @@aut@@ Valentina Guarneri @@aut@@ Domenica Lorusso @@aut@@ Antonio Marchetti @@aut@@ Paolo Marchetti @@aut@@ Nicola Normanno @@aut@@ Barbara Pasini @@aut@@ Matilde Pensabene @@aut@@ Sandro Pignata @@aut@@ Paolo Radice @@aut@@ Enrico Ricevuto @@aut@@ Anna Sapino @@aut@@ Pierosandro Tagliaferri @@aut@@ Pierfrancesco Tassone @@aut@@ Chiara Trevisiol @@aut@@ Mauro Truini @@aut@@ Liliana Varesco @@aut@@ Antonio Russo @@aut@@ Stefania Gori @@aut@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
718627814 |
id |
DOAJ086653156 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ086653156</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311052523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/diagnostics9040146</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086653156</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ602ff62a14b84094a5b190129f3575ac</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<brca1/2</i< assays</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic brca</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-1i</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Barberis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Angela Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fiamma Buttitta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Carrera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicoletta Colombo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Cortesi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Genuardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Gion</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Normanno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbara Pasini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matilde Pensabene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Radice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Enrico Ricevuto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Sapino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierosandro Tagliaferri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfrancesco Tassone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Trevisiol</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Truini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liliana Varesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diagnostics</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">9(2019), 4, p 146</subfield><subfield code="w">(DE-627)718627814</subfield><subfield code="w">(DE-600)2662336-5</subfield><subfield code="x">20754418</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4, p 146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/diagnostics9040146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/602ff62a14b84094a5b190129f3575ac</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2075-4418/9/4/146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-4418</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2019</subfield><subfield code="e">4, p 146</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Ettore Capoluongo |
spellingShingle |
Ettore Capoluongo misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General) <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
authorStr |
Ettore Capoluongo |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718627814 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R5-920 |
illustrated |
Not Illustrated |
issn |
20754418 |
topic_title |
R5-920 <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories ngs <i<brca1/2</i< assays somatic brca parp-1i |
topic |
misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General) |
topic_unstemmed |
misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General) |
topic_browse |
misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General) |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Diagnostics |
hierarchy_parent_id |
718627814 |
hierarchy_top_title |
Diagnostics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)718627814 (DE-600)2662336-5 |
title |
<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
ctrlnum |
(DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac |
title_full |
<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
author_sort |
Ettore Capoluongo |
journal |
Diagnostics |
journalStr |
Diagnostics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
txt |
author_browse |
Ettore Capoluongo Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori |
container_volume |
9 |
class |
R5-920 |
format_se |
Elektronische Aufsätze |
author-letter |
Ettore Capoluongo |
doi_str_mv |
10.3390/diagnostics9040146 |
author2-role |
verfasserin |
title_sort |
<i<brca1/2</i< molecular assay for ovarian cancer patients: a survey through italian departments of oncology and molecular and genomic diagnostic laboratories |
callnumber |
R5-920 |
title_auth |
<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
abstract |
In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. |
abstractGer |
In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. |
abstract_unstemmed |
In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
4, p 146 |
title_short |
<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories |
url |
https://doi.org/10.3390/diagnostics9040146 https://doaj.org/article/602ff62a14b84094a5b190129f3575ac https://www.mdpi.com/2075-4418/9/4/146 https://doaj.org/toc/2075-4418 |
remote_bool |
true |
author2 |
Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori |
author2Str |
Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori |
ppnlink |
718627814 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/diagnostics9040146 |
callnumber-a |
R5-920 |
up_date |
2024-07-03T21:59:15.865Z |
_version_ |
1803596811079778304 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ086653156</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311052523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/diagnostics9040146</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086653156</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ602ff62a14b84094a5b190129f3575ac</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<brca1/2</i< assays</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic brca</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-1i</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Barberis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Angela Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fiamma Buttitta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Carrera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicoletta Colombo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Cortesi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Genuardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Gion</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Normanno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbara Pasini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matilde Pensabene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Radice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Enrico Ricevuto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Sapino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierosandro Tagliaferri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfrancesco Tassone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Trevisiol</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Truini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liliana Varesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diagnostics</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">9(2019), 4, p 146</subfield><subfield code="w">(DE-627)718627814</subfield><subfield code="w">(DE-600)2662336-5</subfield><subfield code="x">20754418</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4, p 146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/diagnostics9040146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/602ff62a14b84094a5b190129f3575ac</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2075-4418/9/4/146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-4418</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2019</subfield><subfield code="e">4, p 146</subfield></datafield></record></collection>
|
score |
7.3974285 |